5177006 enzymatic resolution process

1
338 PATENT ABSTRACTS 5176927 5176997 METHOD OF IMPROVING THE PRODUCTION PROCESS OF DRY CEREAL PRODUCTS BY ENZYME ADDITION Sampsa Haarasilta, Timo Pullinen, Ina Tammersalo-Karsten, Seppo Vaisanen, Harri Franti, Kerava, Finland assigned to Cultor Ltd The invention relates to a method of improving the production process of dry cereal products, such as crispbread and biscuits, by adding hemi- cellulose and cellulose degrading enzymes to the dough. The enzyme addition improves the pro- perties of the dough and increases the process capacity by decreasing the need for dough liquid. DNA PROBE FOR MALE INFERTILITY Michael G Humphreys-Beher assigned to University of Florida The subject invention pertains to a novel means of identifying male infertility. The novel method involves the identification of a unique restriction enzyme digestion pattern which is highly specific to individuals with male sperm binding in- fertility. 5177004 5176996 METHOD FOR MAKING SYNTHETIC OLIGONUCLEOTIDES WHICH BIND SPECIFICALLY TO TARGET SITES ON DUPLEX DNA MOLECULES, BY FORMING A COLINEAR TRIPLEX, THE SYNTHETIC OLIGONUCLEOTIDES AND METHODS OF USE ENZYMATIC DEACYLATION OF ACYL-AMINOSORBOSES Hermann Schutt, Wuppertal, Federal Republic Of Germany assigned to Bayer Aktiengesel- lschaft The present invention relates to an improved process for the preparation of l- desoxynojirimycin. 1-Desoxynojirimycin can be reacted by alkylation on the nitrogen atom to give various saccharase inhibitors which are used therapeutically in the treatment of diabetes mel- litus. Michael E Hogan, Donald J Kessler assigned to Baylor College of Medicine A method for making synthetic oligonucleotides which bind to target sequences in a duplex DNA forming colinear triplexes by binding to the major groove. The method includes scanning genomic duplex DNA and identifying nucleotide target sequences of greater than about 20 nucleotides having either about at least 65% purine bases or about at least 65% pyrimidine bases; and synthesizing synthetic oligonucleotides complementary to identified target sequences. The synthetic oligonucleotides have a G when the complementary location in the DNA duplex has a GC base pair and have a T when the complementary location in the DNA duplex has an AT base pair. The synthetic oligonucleotides are oriented 5' to 4' and bind parallel or 3' to 5' and bind anti-parallel to the about at least 65% purine strand. 5177006 ENZYMATIC RESOLUTION PROCESS Jeffrey M Howell, Ramesh Patel, Laszlo J Szarka assigned to E R Squibb & Sons Inc A novel enzymatic resolution process for pre- paring resolved compounds of the formula See Patent for Chemical Structure I' with improved yields and high optical purity is disclosed. Com- pounds of formula I' are useful, for example, as intermediates for the preparation of phys- iologically active compounds, e.g. captopril, zofenopril and endopeptidase inhibitor.

Upload: doankhanh

Post on 31-Dec-2016

218 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: 5177006 Enzymatic resolution process

338 PATENT ABSTRACTS

5176927 5176997

M E T H O D O F I M P R O V I N G T H E P R O D U C T I O N P R O C E S S O F D R Y C E R E A L P R O D U C T S B Y E N Z Y M E

A D D I T I O N

Sampsa Haarasilta, Timo Pullinen, Ina Tammersalo-Karsten, Seppo Vaisanen, Harri Franti, Kerava, Finland assigned to Cultor Ltd

The invention relates to a method of improving the production process of dry cereal products, such as crispbread and biscuits, by adding hemi- cellulose and cellulose degrading enzymes to the dough. The enzyme addition improves the pro- perties of the dough and increases the process capacity by decreasing the need for dough liquid.

D N A P R O B E F O R M A L E I N F E R T I L I T Y

Michael G Humphreys-Beher assigned to University of Florida

The subject invention pertains to a novel means of identifying male infertility. The novel method involves the identification of a unique restriction enzyme digestion pattern which is highly specific to individuals with male sperm binding in- fertility.

5177004

5176996

M E T H O D F O R M A K I N G S Y N T H E T I C

O L I G O N U C L E O T I D E S W H I C H B I N D S P E C I F I C A L L Y T O T A R G E T

S I T E S O N D U P L E X D N A M O L E C U L E S , B Y F O R M I N G A

C O L I N E A R T R I P L E X , T H E S Y N T H E T I C

O L I G O N U C L E O T I D E S A N D M E T H O D S O F U S E

E N Z Y M A T I C D E A C Y L A T I O N O F A C Y L - A M I N O S O R B O S E S

Hermann Schutt, Wuppertal, Federal Republic Of Germany assigned to Bayer Aktiengesel- lschaft

The present invention relates to an improved process for the preparation of l- desoxynojirimycin. 1-Desoxynojirimycin can be reacted by alkylation on the nitrogen atom to give various saccharase inhibitors which are used therapeutically in the treatment of diabetes mel- litus.

Michael E Hogan, Donald J Kessler assigned to Baylor College of Medicine

A method for making synthetic oligonucleotides which bind to target sequences in a duplex DNA forming colinear triplexes by binding to the major groove. The method includes scanning genomic duplex DNA and identifying nucleotide target sequences of greater than about 20 nucleotides having either about at least 65% purine bases or about at least 65% pyrimidine bases; and synthesizing synthetic oligonucleotides complementary to identified target sequences. The synthetic oligonucleotides have a G when the complementary location in the DNA duplex has a GC base pair and have a T when the complementary location in the DNA duplex has an AT base pair. The synthetic oligonucleotides are oriented 5' to 4' and bind parallel or 3' to 5' and bind anti-parallel to the about at least 65% purine strand.

5177006

E N Z Y M A T I C R E S O L U T I O N P R O C E S S

Jeffrey M Howell, Ramesh Patel, Laszlo J Szarka assigned to E R Squibb & Sons Inc

A novel enzymatic resolution process for pre- paring resolved compounds of the formula See Patent for Chemical Structure I' with improved yields and high optical purity is disclosed. Com- pounds of formula I' are useful, for example, as intermediates for the preparation of phys- iologically active compounds, e.g. captopril, zofenopril and endopeptidase inhibitor.